samedan logo
 
 
spacer
home > ebr > spring 2004 > patently better - the rights and wrongs of patent protection drug discovery technology
PUBLICATIONS
European Biopharmaceutical Review

Patently Better - The Rights and Wrongs of Patent Protection Drug Discovery Technology

Whether to secure development funding, protect product licence fees or simply to stop third parties profiting from the fruits of their research, the patent is an essential business tool for firms in the biopharmaceutical field. This article looks at the essential role that patents play, and explores some important recent changes affecting the availability of patent protection.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gareth Williams is a Patent Attorney and European Trade Mark Attorney at Marks and Clerk. Gareth obtained an honours degree in Biological Sciences from Oxford University, where he remained to complete a doctorate in Molecular Biology and Genetics researching the Y chromosome, funded as part of the Human Genome Project. He entered the patent profession in 1998 and is a qualified UK and European Patent Attorney. He has acted for clients in a variety of fields, but specialises particularly in patent work in the fields of biotechnology, medical devices, business method inventions and mechanical devices. His practice involves the drafting, filing and prosecution of patent applications worldwide, the handling of opposition and appeal work at the European Patent Office, and advice on infringement matters and general intellectual property strategy.

spacer
Gareth Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th


More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

INTERPHEX_2017

21-23 March 2017, Javits Center, New York, NY USA

All of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. For 38 years, INTERPHEX is the premier pharmaceutical, biotechnology, and medical device development and manufacturing event where you can “Experience Science through Commercialization”. Based in New York, INTERPHEX brings over 10,500 global industry professionals and 625+ suppliers together to “Learn It, Experience It, Procure It” through a unique combination of our no cost technical conference, exhibits, demonstrations, partnering opportunities, and networking events to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement